



Attorney Docket No. 9013-31

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Welch et al.

Serial No.: 09/889,645

Filed: January 24, 2002

For: TREATING PROTEIN-CONTAINING LIQUIDS

Confirmation No. 8639

Group Art Unit: 1648

Examiner: Ulrike Winkler

October 17, 2005

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)**

Sir:

Attached is a Form PTO-1449 together with a copy of the cited document. It is requested that this document be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

This Information Disclosure is submitted in accordance with 37 C.F.R. § 1.97(b)(4), before the mailing of a first action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

Shawna Cannon Lemon
Registration No. 53,888

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428, Raleigh, NC 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EV 674756500 US

Date of Deposit: October 17, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan E. Freedman

Date of Signature: October 17, 2005

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Sheet	1	of	1
-------	---	----	---

Application Number	09/889,645
Filing Date	01/24/2002
First Named Inventor	Anne Welch
Group Art Unit	1648
Examiner Name	Ulrike Winkler
Attorney Docket Number	9013-31

[illegible][illegible]

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	Reichl et al., "Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin," <i>Vox Sanguinis</i> , 83:137-145 (2002)	

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.